Angiogenic Activity of Sera from Pulmonary Tuberculosis Patients in Relation to IL-12p40 and TNFα Serum Levels by Zielonka, Tadeusz M. et al.
TUBERCULOSIS
Angiogenic Activity of Sera from Pulmonary Tuberculosis
Patients in Relation to IL-12p40 and TNFa Serum Levels
Tadeusz M. Zielonka • Urszula Demkow • Dorota Michalowska-Mitczuk •
Malgorzata Filewska • Beata Bialas • Katarzyna Zycinska •
Michael H. Obrowski • Jan Kus • Ewa Skopinska-Rozewska
Received: 2 February 2010/Accepted: 3 April 2011/Published online: 21 May 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract The role of angiogenesis in the pathogenesis of
tuberculosis (TB) is not clear. The aim of this study was to
examine the effect of sera from TB patients on angiogen-
esis induced by different subsets of normal human mono-
nuclear cells (MNC) in relation to IL-12p40 and TNFa
serum levels. Serum samples from 36 pulmonary TB
patients and from 22 healthy volunteers were evaluated. To
assess angiogenic reaction the leukocytes-induced angio-
genesis test according to Sidky and Auerbach was per-
formed. IL-12p40 and TNFa serum levels were evaluated
by ELISA. Sera from TB patients signiﬁcantly stimulated
angiogenic activity of MNC compared to sera from healthy
donors and PBS (p\0.001). The number of microvessels
formed after injection of lymphocytes preincubated with
sera from TB patients was signiﬁcantly lower compared to
the number of microvessels created after injection of MNC
preincubated with the same sera (p\0.016). However, the
number of microvessels created after the injection of
lymphocytes preincubated with sera from healthy donors or
with PBS alone was signiﬁcantly higher (p\0.017). The
mean levels of IL-12p40 and TNFa were signiﬁcantly
elevated in sera from TB patients compared to healthy
donors. We observed a correlation between angiogenic
activity of sera from TB patients and IL-12p40 and TNFa
serum levels (p\0.01). Sera from TB patients constitute a
source of mediators that participate in angiogenesis and
prime monocytes for production of proangiogenic factors.
The main proangiogenic effect of TB patients’ sera is
mediated by macrophages/monocytes. TNFa and IL-12p40
may indirectly stimulate angiogenesis in TB.
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Introduction
Angiogenesis from preexisting vasculature occurs in many
pathological conditions such as tumors [1], cardiovascular
diseases [2], chronic inﬂammation [2, 3], rheumatoid
arthritis [4], diabetic retinopathy [5], endometriosis [6],
and obesity [7]. In pulmonary nonmalignant diseases
angiogenesis has been implicated in the pathogenesis of
idiopathic interstitial pneumonia [8], lung ﬁbrosis induced
by bleomycin [9], and sarcoidosis [10]. Vascular endo-
thelial growth factor (VEGF) is a fundamental regulator
of normal and pathological angiogenesis [11]. Ischemia
induces both VEGF production and angiogenesis [12].
Although there have been reports concerning angiogenesis
in infectious diseases, its role in the pathogenesis of TB
has not been determined [13, 14]. Serum VEGF might be
a useful marker as a prognostic indicator in sarcoidosis
[15] and other granulomatous diseases, including TB.
Increased VEGF levels in serum [16–18], pleural ﬂuid
[19, 20] and cerebrospinal ﬂuid [21] have been found in
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DOI 10.1007/s00408-011-9291-6patients with active TB. VEGF therefore may be associ-
ated with the pathogenesis of pulmonary TB in the
development of the chronic inﬂammatory reaction [18].
M. tuberculosis antigens are considered an important
factor participating in the pathogenesis of Eales’ dis-
ease—an idiopathic retinal periphlebitis characterized by
capillary nonperfusion and angiogenesis [22]. In one
study, an intense angiogenesis was shown ultrastructurally
in active pulmonary tuberculosis lesions [23], but the
meaning of this phenomenon is not completely understood
yet. An important role in the pathogenesis of TB and also
in the modulation of angiogenesis is played by some
cytokines, especially IL-12 and TNFa [24–26]. The aim
of this study was to examine the effect of sera from TB
patients on angiogenesis induced by different subsets
of normal human mononuclear cells (MNC) in relation to
IL-12p40 and TNFa serum levels.
Materials and Methods
Study Population
The study was approved by the local ethics committee.
Serum samples were obtained from 36 patients with active
pulmonary TB and from 22 healthy volunteers. The TB
group consisted of 26 male and 10 female patients aged
49.8 ± 14.9 years (range = 23-75 years). All were HIV-
negative and 23 were smokers. The diagnosis of pulmonary
TB was conﬁrmed by a conventional sputum culture. No
systemic or extrapulmonary TB was observed. Blood
samples were taken from patients before antituberculosis
treatment was started. As a control, sera from 22 healthy
nonsmoking volunteers were used (12 women and 10 men,
mean age = 38.7 ± 11.4, range = 20-58 years). None of
the control volunteers had any past medical history of
tuberculosis, other pulmonary diseases, or cancer.
Preparation of Peripheral Blood Mononuclear Cells
Blood from healthy donors attending the Warsaw Central
Blood Bank was collected in a heparinized syringe, then
diluted 1:1 in phosphate-buffered saline (PBS) and layered
over Lymphoprep separation medium (Sigma). After
spinning the tubes for 20 min at 500 g, the mononuclear
fraction was aspirated from the interface. MNC viability
estimated by trypan blue stain was C 98%. This method
yielded MNC preparation containing 10-15% monocytes
and 85-90% lymphocytes based on morphologic criteria
and myeloperoxidase staining. MNC were depleted of
monocytes by glass adherence and phagocytosis of iron
particles using 15 mg for 10 9 10
6 cells.
Leukocyte-induced Angiogenesis Assay (LIA)
To assess the effect of sera from TB patients on angio-
genesis induced by different fractions of MNC, a leuko-
cyte-induced angiogenesis test described by Sidky and
Auerbach in an animal model [27] with modiﬁcation [10,
28] was used. The local ethical commission for experi-
menting on animals approved all procedures involved in
this study. Female inbred 8-week-old BALB/c mice served
as recipients of MNC or lymphocytes preincubated in PBS
supplemented with 25% of serum from TB patients or from
healthy volunteers for 1 h at 37C. As a control, other mice
were given MNC or lymphocytes that were preincubated
only in PBS. Mice were anesthetized with 3.6% chloral
hydrate (POCH, Poland) and injected intradermally with
5 9 10
5 cells in Parker liquid (6 injections per mice and 3
mice for each tested patient). The mice were killed after
3 days. The newly formed blood vessels were identiﬁed
and counted on the inner surface of the skin of each mouse
using a microscope (Nikon, Japan) at 6 9 magniﬁcation. In
all cases identiﬁcation was performed by one expert (UD)
based on the previously described criteria [27].
Cytokines
IL-12p40 and TNFa in sera were evaluated by enzyme-
linked immunosorbent assay (ELISA) using commercially
available kits (BIOSOURCE Europe S.A.) according to the
manufacturer’s instructions. Recombinant TNFa (NIBSC,
Hertfordshire, UK, EN6 3 QG) was used as a standard.
Concentrations of IL-12p40 in sera were determined by
sandwich ELISA using speciﬁc IL-12p40 MoAb. Optical
density was measured at 450 nm using spectrophotometric
reader Elx800 (Biotek Instruments, Inc., USA).
Statistical Analysis
The value of the angiogenesis test was expressed as an
angiogenesis index (AI):
AI ¼ Aex=Acontr
where Aex is the mean number of micro blood vessels
created after the injection of MNC or lymphocytes prein-
cubated in PBS with the serum of a patient or healthy
donor, and Acontr is the mean number of micro blood ves-
sels created after the injection of MNC or lymphocytes
preincubated with PBS alone
All results are presented as mean ± SD. Statistical
evaluation of the results was performed using Pearson’s
test, Student’s t-test, and Mann-Whitney test (Statistica 6
for Windows, Statsoft, Tulsa, OK, USA). A p value\0.05
was used to indicate statistical signiﬁcance.
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123Results
Angiogenic activity of MNC was measured by the mean
number of newly formed vessels after injection of MNC
preincubated with sera and PBS or with PBS alone. Sera
from TB patients signiﬁcantly indirectly stimulated angio-
genesis to a greater extent than sera from healthy donors or
PBS alone (p\0.001) (Fig. 1). Proangiogenic activity of
sera from TB patients (mean number of microves-
sels = 16.9 ± 0.9) was signiﬁcantly higherthan thatof sera
from healthy donors (13.99 ± 0.73 vessels; p\0.001).
However, sera from healthy donors also signiﬁcantly
(p\0.001) stimulated angiogenic activity of normal MNC
compared to MNC preincubated only with PBS (12.7 ±
1.16 vessels).
Following the injection of lymphocytes preincubated
with sera from 20 TB patients, the mean number of
microvessels signiﬁcantly decreased (16 ± 1.33; p\0.05)
compared to the number of microvessels after the injection
of a full suspension of MNC preincubated with the same
sera (17 ± 0.79) (Fig. 2a). However, the mean number of
microvessels after injection of lymphocytes preincubated
with sera from healthy donors signiﬁcantly increased (from
13.99 ± 0.73 to 14.8 ± 1.0; p\0.01) compared to the
number of microvessels after the injection of a full sus-
pension of MNC preincubated with the same sera (Fig. 2b).
A similar effect was observed in the control group when
MNC or lymphocytes were preincubated with PBS alone
(increase from 12.7 ± 1.16 to 13.8 ± 1.63; p\0.05)
(Fig. 2c). The results were expressed as an angiogenic
index and the following relationships were observed: After
injection of MNC preincubated with sera from TB patients,
AI was 1.29 ± 0.03 but it signiﬁcantly decreased
(1.12 ± 0.09; p\0.001) following preincubation of lym-
phocytes with sera from TB patients. However, following
the injection of lymphocytes preincubated with sera from
healthy volunteers, AI remained the same as after the
injection of MNC preincubated with sera from healthy
volunteers (1.06 ± 0.04 vs. 1.07 ± 0.06).
The IL-12p40 serum level was signiﬁcantly elevated in
TB patients (355 ± 279 pg/ml; p\0.01) compared to that
of healthy controls (64 ± 70 pg/ml) (Fig. 3a). A signiﬁ-
cant correlation was found between the IL-12p40 serum
level and angiogenic properties of sera of the examined
patients and healthy donors (r = 0.57, p\0.01) (Fig. 4a).
TNFa serum level from TB patients (31 ± 8 pg/ml;
p\0.002) was signiﬁcantly elevated compared to that of
healthy controls (21 ± 3.4 pg/ml) (Fig. 3b). A signiﬁcant
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123correlation (r = 0.62, p\0.01) between TNFa serum
level and angiogenic activity of sera was found (Fig. 4b).
Discussion
These results conﬁrm suggestions [16, 17] of the involve-
ment of angiogenesis in TB. The positive correlation
between angiogenic activity measured by the number of
newly created vessels after the injection of MNC prein-
cubated with sera of TB patients and IL-12p40 and TNFa
serum concentration levels seems to suggest that these
cytokines play an important role in the pathogenesis of the
neovascularization [29, 30]. Our previous studies carried
out on the same model did not conﬁrm any correlation
between angiogenic activity of sarcoidosis patients’ sera
and IL-6 and IL-8 serum levels [10]. However, TNFa,a n
important proinﬂammatory factor, may stimulate angio-
genesis in interstitial lung diseases, and a weak correlation
was observed between the serum level of IL-12 and the
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123number of new vessels created after intradermal injection
of MNC preincubated with sera from interstitial lung dis-
eases patients [31, 32]. Our results support the hypothesis
about the possible link between angiogenic activity of TB
patients’ sera and IL-12 and TNFa. These cytokines, which
play an important role in the pathogenesis of TB, also
modulate angiogenesis [25, 26, 29, 30]. Signiﬁcant corre-
lations between the concentration of these cytokines and
radiological ﬁndings in TB patients were found [24]. Some
reports point to neovascularization in the pathogenesis
of tuberculosis. Thus, Abe et al. [16] suggest that the
increased blood vessel formation and oxygen supply
caused by the overexpression of VEGF inhibits cavity
formation in TB. However, studies of Alatas et al. [17] did
not conﬁrm these ﬁndings. These authors observed a sig-
niﬁcant increase of VEGF serum level in active TB, and a
decrease with effective antituberculosis treatment [17].
Matsuyama et al. [18] reported higher VEGF levels in the
sera of patients with active pulmonary TB. Mycobacterium
tuberculosis-infected monocytes develop a matrix-degrad-
ing phenotype [33]. Matrix degradation is the essential ﬁrst
step in the process of creating new vessels from the
preexisting vasculature. In TB meningitis, monocytes
secrete matrix metalloproteinase-9, which facilitates leu-
kocyte migration across the blood-brain barrier [34]. TNFa
plays an important role in this process as well [33]. Lipo-
arabinomannan, one of the main M tuberculosis antigens,
stimulates macrophages to release metalloproteinase-9,
which, by breaking down proteins, not only causes forma-
tion of cavities but also induces angiogenesis [35]. A cor-
relation between VEGF and TNFa was also observed in the
pathogenesis of exudate in tuberculous pleuritis [20]. TNFa
is produced by various cells in the inﬂammatory site and
induces angiogenic cytokines, including IL-8, VEGF, and
basic ﬁbroblast growth factor (bFGF), all of which
are involved in neovascularization [36]. Saita et al. [37]
demonstrated that intracorneal challenge with trehalose
6,60-dimycolate derived from M tuberculosis induces an
inﬂammatory response, including granuloma formation and
neovascularization. The angiogenic reaction was inhibited
by neutralizing antibodies targeting VEGF and IL-8, par-
tially by anti-TNFa antibodies, but not by anti-IL-1b [37].
Macrophages stimulated with cord factor produce proin-
ﬂammatory type-1 helper-T-cell-inducing cytokines,
including TNFa, IL-1, chemotactic factors, and IL-12 [38].
In time it leads to the increase of VEGF concentration [38].
Establishing the key role of the monocytes in inducing
angiogenic activity when affected by sera of TB patients is
an important result of this study. The angiogenic effect of
TB patients’ sera was different than that of sera from
healthy donors. Healthy human sera stimulated stronger
lymphocytes than monocytes. In the case of TB patients,
depletion of monocytes from MNC decreased the proan-
giogenic effect of the sera; therefore, the proangiogenic
factors present in the patients’ sera stimulated mainly
monocytes and had no such strong effect on lymphocytes.
From this observation we may conclude that the main
proangiogenic effect of TB patients’ sera is mediated by
macrophages/monocytes. Matsuyama et al. [18] showed by
immunohistochemistry that the expression of VEGF
occurred in the alveolar macrophages around active TB
lesions. It has been demonstrated that VEGF plays a role in
the pathogenesis of pulmonary M avium complex infection
[39]. Therefore, it can be assumed that activated macro-
phages are the main cells that secrete VEGF in TB lesions
when affected by factors such as IL-12 and TNFa. Pul-
monary TB and sarcoidosis are granulomatous diseases and
their pathogenesis has been linked to monocytes and
alveolar macrophages [40, 41]. Meyer et al. [42] pointed
out the key role of monocytes from sarcoidosis patients in
stimulating neovascularization. In an earlier study we also
demonstrated that sera from sarcoidosis patients prime
monocytes for production of proangiogenic factors [10].
Sakaguchi et al. [43] indicated that trehalose 6,60-dimy-
colate augments VEGF production by neutrophils and
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123macrophages and induces neovascularization in granu-
lomatous tissue. Chronic inﬂammation in TB is charac-
terized by a localized accumulation of mononuclear cells,
i.e., the formation of a granuloma that is surrounded by
neovascularization [41]. Angiogenesis is required for the
progression of chronic inﬂammation [3].
IL-12 is a multifunctional cytokine produced by mac-
rophages and dendritic cells. As a factor promoting the
commitment of naı ¨ve lymphocytes to a Th1-type proﬁle of
cytokine expression, IL-12 may be pivotal in the cascade
of proinﬂammatory events in the lungs [44]. The number
of cells expressing Th1-type cytokines such as INFc and
IL-12 is increased within the lungs of patients with gran-
ulomatous disease such as TB and sarcoidosis [29]. IL-12
not only stimulates the growth of T and NK cells but also
inhibits angiogenesis in solid tumors [45]. IL-12 is a
heterodimeric cytokine composed of p40 and p34 chains.
The subunit of IL-12p40 is in a free form, which blocks
speciﬁc receptors to stimulate angiogenesis; this deter-
mined the selection of this cytokine for this study. Hete-
rodimeric IL-12 and free p40 were present in tuberculous
pleural effusions but not in malignant pleural effusions,
suggesting that IL-12 is produced in the local immune
response to infection [46]. Cooper et al. [47] have dem-
onstrated that IL-12p40 knockout mice are defective in
their ability to induce INFc production and to generate a
protective Th1-type of immunologic response in TB. IL-12
proved to be an effective and successful adjuvant to a
standard treatment in patients suffering from progressive
clinical TB [48].
It is difﬁcult to determine whether neovascularization
plays a beneﬁcial or a harmful role in the course of TB. It
can only be assumed that the growth of a localized
inﬂammatory mass requires neovascularization. Insufﬁ-
cient angiogenesis resulting in hypoxia creates favorable
conditions for tissue necrosis and cavity formation.
Therefore, further research on neovascularization and its
role in the pathogenesis of TB is necessary.
Conclusions
Sera from TB patients constitute a source of mediators
participating in angiogenesis. Sera from TB patients prime
monocytes for production of proangiogenic factors. TNFa
and IL-12p40 as important proinﬂammatory factors may
stimulate angiogenesis in TB.
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